Literature DB >> 26940714

In Vitro Skin Models and Their Predictability in Defining Normal and Disease Biology, Pharmacology, and Toxicity.

Dimitry M Danilenko1, Gail D Lewis Phillips2, Dolores Diaz3.   

Abstract

In vitro skin model systems are increasingly being used both in the early evaluation of therapeutic drug candidates and in confirmatory mechanistic studies. The most commonly used of these in vitro model systems are reconstituted human epidermis (RHE) models. These RHE models consist solely of epidermal keratinocytes, which comes with some limitations but also with the advantage of focusing toxicologic and pharmacologic evaluation on keratinocytes alone. RHE models can generally be implemented more quickly, easily, and reproducibly than in vivo models and can thus be used for high throughput compound screening while potentially reducing the need for animal studies. Histologic evaluation of RHE sections can be done quite easily, and the sections are very amenable to quantification via image analysis, including automated analysis. RHE model systems can provide very valuable early indications of therapeutic candidate biology, pharmacology, and toxicity; and early results have demonstrated that RHE models have been quite predictive for in vivo pharmacologic and toxicologic effects on the skin, including clinical skin toxicity.
© The Author(s) 2016.

Entities:  

Keywords:  in vitro; keratinocytes; pharmacology; skin; toxicity

Mesh:

Year:  2016        PMID: 26940714     DOI: 10.1177/0192623316632074

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  7 in total

Review 1.  Engineered Skin Tissue Equivalents for Product Evaluation and Therapeutic Applications.

Authors:  Sana Suhail; Naseem Sardashti; Devina Jaiswal; Swetha Rudraiah; Manoj Misra; Sangamesh G Kumbar
Journal:  Biotechnol J       Date:  2019-05-17       Impact factor: 4.677

2.  Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability.

Authors:  Donna W Lee; Shelly Zhong; Rama Pai; Julie Rae; Siddharth Sukumaran; Eric G Stefanich; Jeff Lutman; Estelle Doudement; Xiaoting Wang; Brandon Harder; Annemarie Lekkerkerker; Ann Herman; Wenjun Ouyang; Dimitry M Danilenko
Journal:  Pharmacol Res Perspect       Date:  2018-11-15

3.  Skin Toxicity Assessment of Silver Nanoparticles in a 3D Epidermal Model Compared to 2D Keratinocytes.

Authors:  Liang Chen; Meiyu Wu; Shan Jiang; Yanyun Zhang; Runzhi Li; Yongbo Lu; Lin Liu; Gang Wu; Ying Liu; Liming Xie; Liming Xu
Journal:  Int J Nanomedicine       Date:  2019-12-09

4.  EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.

Authors:  Nicolas Joly-Tonetti; Thomas Ondet; Mario Monshouwer; Georgios N Stamatas
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

5.  Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.

Authors:  Honglin Jiang; Ryan K Muir; Ryan L Gonciarz; Adam B Olshen; Iwei Yeh; Byron C Hann; Ning Zhao; Yung-Hua Wang; Spencer C Behr; James E Korkola; Michael J Evans; Eric A Collisson; Adam R Renslo
Journal:  J Exp Med       Date:  2022-03-09       Impact factor: 17.579

6.  Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies.

Authors:  Analia Rodríguez-Garzotto; Lara Iglesias-Docampo; C Vanesa Díaz-García; Isabel Ruppen; Pilar Ximénez-Embún; Carlos Gómez; J Luis Rodríguez-Peralto; Javier Ortiz de Frutos; Jose A Lopez-Martin; Cristina Grávalos; Hernán Cortés-Funes; M Teresa Agulló-Ortuño
Journal:  Ther Adv Med Oncol       Date:  2022-03-26       Impact factor: 8.168

7.  Evaluation of native and non-native biomaterials for engineering human skin tissue.

Authors:  Carolina Motter Catarino; Katharina Kaiser; Tânia Baltazar; Luiza Motter Catarino; Jonathan R Brewer; Pankaj Karande
Journal:  Bioeng Transl Med       Date:  2022-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.